CpG andDcMNPs |
|
Vaxjo ID |
320 |
|
Vaccine Adjuvant Name |
CpG andDcMNPs |
|
Adjuvant VO ID |
VO_0005577
|
|
Description |
CpG-oligodeoxynucleotide (CpG-ODN) functions as an immune adjuvant. It is used in conjunction with PAMAM dendrimer-coated magnetic nanoparticles (DcMNPs) to treat human breast cancer cells, evaluating its effect on apoptosis-regulating genes and cytokine release. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
CpG-ODN conjugated with PAMAM dendrimer-coated magnetic nanoparticles (DcMNPs) |
|
Structure |
CpG-oligodeoxynucleotide, PAMAM dendrimer-coated magnetic nanoparticles |
|
Preparation |
CpG-ODN conjugated with PAMAM dendrimer-coated magnetic nanoparticles (DcMNPs) is mentioned, but specific preparation details are N/A. |
|
Function |
CpG-ODN conjugated with PAMAM-coated nanoparticles (CpG/DcMNPs) induces apoptosis in breast cancer cells by increasing pro-apoptotic genes (Noxa, Bax) and decreasing anti-apoptotic genes (Survivin, c-Flip). It also raises IL-6 release in some cells, suggesting CpG-ODN’s cytotoxic effect involves apoptosis gene regulation and cytokine modulation. |
| References |
Taghavi and Gunduz, 2016: Taghavi Pourianazar N, Gunduz U. Changes in apoptosis-related gene expression and cytokine release in breast cancer cells treated with CpG-loaded magnetic PAMAM nanoparticles. International journal of pharmaceutics. 2016; 515(1-2); 11-19. [PubMed: 27717915].
|
